Article Text

Download PDFPDF
▼Meloxicam-a safer NSAID?
  • Relevant BNF section: 10.1.1.


Non-steroidal anti-inflammatory drugs (NSAIDs) block the enzyme cyclo-oxygenase (COX), thereby reducing the synthesis of prostaglandins from arachidonic acid. This blockade is believed to be responsible for both the therapeutic (anti-inflammatory) and many of the unwanted effects of NSAIDs.1 It is now recognised that COX exists in two functionally distinct isoforms: COX-1 is active continuously and catalyses the synthesis of prostaglandins with physiologically protective effects (e.g. on the gastric mucosa), while COX-2 is induced during inflammation.2,3 ▼Meloxicam (Mobic - Boehringer Ingelheim), which has been available in the UK for 2 years, is marketed as an NSAID with "COX-2 selectivity" in vitro, and so one which "in theory...should have a better GI side-effect profile". Is meloxicam an advance on traditional NSAIDs?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 10.1.1.

View Full Text